Redx has been presented with a commemorative plaque at its HQ at Alderley Park, in recognition of its discovery of pirtobrutinib, the active pharmaceutical ingredient (API) in Eli Lilly's cancer treatment Jaypirca.
OSP spoke to Vladamir Penkrat, head of safety and regulatory and Shuba Rao a senior director at Indegene, a life sciences digital company about a paper they recently published called 'Challenges and Future of PV Compliance' about the direction...
Poolbeg Pharma plc has been granted a patent by the US Patent and Trademark Office (USPTO) for ways of treating hypercytokinaemia using a small molecule immunomodulator.
The company is using a ‘lab-in-the-loop’ process to advance the drug discovery process, and stated that opening a new lab space represents a step forward on its path to ‘transform drug discovery’.
The US Food and Drug Administration (FDA) has accepted Merck’s Prevymis (letermovir) for prophylaxis of cytomegalovirus (CMV) disease in kidney transplant patients for priority review.
Evidence shows that animal models currently dominating bioavailability estimates are poor predictors and human, cell-based multi-organ microphysiological systems (MPS) should be investigated, CN Bio says.
The partners have come together to apply artificial intelligence to phenotypic drug screening, with the aim of developing therapies in different therapeutics areas.
TransCelerate BioPharma continues to work towards “bringing new medicines to patients faster”. We caught up with the organization’s CEO to hear about its main achievements over the past decade and learn about what comes next.
UK-based biopharmaceutical company, PhoreMost, is to deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER, toward disease-relevant pathways nominated by Roche.
The pharma company’s collaboration with the drug discovery specialist involves using artificial intelligence to discover and develop up to five drug targets.
The pharmaceutical company and the artificial intelligence pathology specialist will focus on translational research in oncology, fibrosis, and immunology.
The AI and QC specialists have joined to use AI and QC in order to discover biological pathways relevant to the treatment of triple-negative breast cancer.
A leader from pharmaceutical firm Astellas discusses how the company has put to use a discovery platform that combines human expertise, AI, and robotics.
A leader from healthcare commercial intelligence company Definitive Healthcare discusses the rise of precision medicine and the benefits the field can yield.
The health care system and analytics company are joining on the ASAP study, a program that constitutes a five-year commitment to advancing cancer solutions.
The drug company, which uses artificial intelligence to discover and advance repurposed drugs, is harnessing the technology to find a treatment for Crohn’s.
With Veeva Link for Key People, LEO Pharma is looking to deepen its efforts to engage with knowledgeable medical professionals in the dermatology community.
The CRO has paired with the drug discovery technology firm on Logica, an artificial intelligence tool designed to accelerate development of new treatments.
Newly launched life sciences company Sionna Therapeutics has secured funding to fuel discovery and development of drug candidates to treat cystic fibrosis.
Experts from the Decentralized Trials and Research Alliance and Rafael Pharmaceuticals discuss progress and possibilities during Clinical Development Advances.
The US- and Hungary-based pharma firms will work on research, development, and commercialization of dopamine receptor modulators for potential treatments.
The drug company has renewed its arrangement with the artificial intelligence specialist, centered on using AI to improve understanding of the immune system.
The drug discovery firm will work with the Dean Felsher Laboratory, using the company’s transomics platform to discover therapies for untreatable cancers.
Returning to an in-person format March 21-24, the industry event is bringing a range of networking, educational, and social programming to New York City.
A leader from the artificial intelligence insights specialist talks discusses how the effective use of advanced analytics can lead to a number of benefits.
The artificial intelligence-driven drug discovery company has dosed its first healthy volunteer in a trial for a candidate to treat idiopathic pulmonary fibrosis.
The pharmaceutical company currently has several promising treatments in development for gastroenterological, dermatological, and cardiological conditions.
According to a leader from Cytoreason, AI isn’t necessarily the best or only tool suited to discover new and novel therapies—it might take a human touch.
The Oxford-GSK Institute of Molecular and Computational Medicine has been created via a five-year collaboration between GlaxoSmithKline and the University of Oxford.
The AI technology firm and pharma services company are joining to help one of the country’s leading pharmaceutical firms develop a promising drug candidate.
This month’s roundup of new technology, equipment, and industry partnerships includes news from IBM, IQVIA, Mediata, Labcorp, and other notable companies.
The drug discovery company reportedly used AI-powered drug discovery to come up with a promising preclinical candidate for treatment of the kidney ailment.
According to a leader from Saama Technologies, keeping competitive in the face of technology evolution requires staff that can keep up with the changes.
This month’s roundup of new equipment, materials, digital solutions and other news includes items from Lonza, Waters, Eversana, Clinical Ink, and more.
Sosei Heptares and PharmEnable will harness artificial intelligence-enabled technology and advanced chemistry to explore neurological disease solutions.
Exploring alternative uses for drugs tapped for other indications, can save considerable time and money in discovery, according to an expert from the CRO.
The drug delivery platform company is exploring the viability of remdesivir and other potential treatments for the virus using its DehydraTECH technology.
